Key Statistics for Bladder Cancer. 2022. Updated 1/12/2022. https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed 13 July 2022.
Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 18 June 2022.
Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–4. https://doi.org/10.1111/iju.13376.
Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.
Article CAS PubMed Google Scholar
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683.
Article CAS PubMed PubMed Central Google Scholar
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. https://doi.org/10.1016/S1470-2045(17)30065-7.
Article CAS PubMed Google Scholar
Apolo AB, Ellerton JA, Infante JR, et al. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN solid tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020;8(2):e001246. https://doi.org/10.1136/jitc-2020-001246.
Article PubMed PubMed Central Google Scholar
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8. https://doi.org/10.1038/nature12213.
Article CAS PubMed PubMed Central Google Scholar
Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56. https://doi.org/10.1016/j.cell.2017.09.007. (e25).
Article CAS PubMed PubMed Central Google Scholar
Al-Ahmadie H, Netto GJ. Molecular pathology of urothelial carcinoma. Surg Pathol Clin. 2021;14(3):403–14. https://doi.org/10.1016/j.path.2021.05.005.
Article PubMed PubMed Central Google Scholar
Liu Y, Han X, Li L, et al. Role of Nectin4 protein in cancer (Review). Int J Oncol. 2021. https://doi.org/10.3892/ijo.2021.5273.
Article PubMed PubMed Central Google Scholar
Heath EI, Rosenberg JE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93–103. https://doi.org/10.1038/s41585-020-00394-5.
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 2019;31(3):207–15. https://doi.org/10.1097/CCO.0000000000000532.
Tomiyama E, Fujita K, Rodriguez Pena MDC, et al. Expression of Nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21155390.
Article PubMed PubMed Central Google Scholar
Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase i study of single-agent enfortumab vedotin in patients with Nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041–9. https://doi.org/10.1200/jco.19.02044.
Article CAS PubMed PubMed Central Google Scholar
Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989–9006. https://doi.org/10.18632/oncotarget.25615.
Article PubMed PubMed Central Google Scholar
Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–33. https://doi.org/10.1038/onc.2012.36.
Article CAS PubMed Google Scholar
Wang J, Zhang K, Grabowska D, et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Cancer Res. 2011;9(12):1686–95. https://doi.org/10.1158/1541-7786.MCR-11-0241.
Article CAS PubMed PubMed Central Google Scholar
Avellini C, Licini C, Lazzarini R, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8(35):58642–53. https://doi.org/10.18632/oncotarget.17407.
Article PubMed PubMed Central Google Scholar
Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Oncotargets Ther. 2014;7:2227–36. https://doi.org/10.2147/OTT.S46887.
Vlachostergios PJ, Jakubowski CD, Niaz MJ, et al. Antibody-drug conjugates in bladder cancer. Bladder Cancer. 2018;4(3):247–59. https://doi.org/10.3233/BLC-180169.
Article PubMed PubMed Central Google Scholar
Nagayama A, Ellisen LW, Chabner B, Bardia A. Antibody-drug conjugates for the treatment of solid tumors: clinical experience and latest developments. Target Oncol. 2017;12(6):719–39. https://doi.org/10.1007/s11523-017-0535-0.
Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54. https://doi.org/10.1200/JCO.2001.19.13.3244.
Article CAS PubMed Google Scholar
Kim, J. H., & Chang, I. H. (2022). A novel strategy for treatment of bladder cancer: Antibody-drug conjugates. Investigative and clinical urology, 63(4), 373–384. https://doi.org/10.4111/icu.20220061
Article PubMed PubMed Central Google Scholar
Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther. 2020;20(7):551–61. https://doi.org/10.1080/14737140.2020.1782201.
Article CAS PubMed PubMed Central Google Scholar
Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19. https://doi.org/10.1158/1541-7786.Mcr-19-0582.
Article CAS PubMed Google Scholar
Abel M, Burkenroad A, Sun A, Lu E, Stefanoudakis D, Drakaki A. The evolving landscape of antibody-drug conjugates for urothelial carcinoma. Clin Genitourin Cancer. 2021;19(3):183–93. https://doi.org/10.1016/j.clgc.2020.11.006.
Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015–35. https://doi.org/10.1007/s12325-017-0519-6.
Article CAS PubMed PubMed Central Google Scholar
Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–600. https://doi.org/10.1200/jco.19.01140.
Article CAS PubMed PubMed Central Google Scholar
Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–35. https://doi.org/10.1056/NEJMoa2035807.
Article CAS PubMed PubMed Central Google Scholar
Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–82. https://doi.org/10.1016/S1470-2045(21)00094-2.
Article CAS PubMed Google Scholar
Moussa M, Papatsoris A, Abou Chakra M, Dellis A. Profile of enfortumab vedotin in the treatment of urothelial carcinoma: the evidence to date. Drug Des Dev Ther. 2021;15:453–62. https://doi.org/10.2147/DDDT.S240854.
Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6. https://doi.org/10.1016/j.bcp.2015.12.008.
Article CAS PubMed Google Scholar
Muller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741–55. https://doi.org/10.1158/2326-6066.CIR-13-0198.
Article CAS PubMed Google Scholar
Müller P, Kreuzaler M, Khan T, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015;7(315):315ra188. https://doi.org/10.1126/scitranslmed.aac4925.
Article CAS PubMed Google Scholar
Heijden MSVD, Gupta S, Galsky MD, et al. Study EV-302: a two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress). J Clin Oncol. 2022;40(6_suppl):TPS589. https://doi.org/10.1200/JCO.2022.40.6_suppl.TPS589.
Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023. https://doi.org/10.1200/jco.22.01643.
留言 (0)